AZ’ Imfinzi bags new approval for lung cancer
The EC has cleared its use for the treatment of extensive-stage small cell lung cancer
Read More
Tag: durvalumab
Priority review for Imfinzi’s less-frequent dosing regimen
AZ says approval would “simplify and improve treatment by enabling continuity of care while minimising the risk of exposure to infection in the healthcare setting”
Read More
AZ links with ArcherDX to detect minimal residual disease in lung cancer patients
ArcherDX will perform whole exome sequencing of NSCLC patient samples to generate personalised ctDNA assays to test for MRD
Read More
Imfinzi shows survival benefit in aggressive lung cancer
The drug cut the risk of death by 27%.
Read More
AZ’ Imfinzi combo fails lung cancer study
The drug giant reported that in the primary analysis population the combination did not meet the primary endpoint.
Read More
Imfinzi found to improve survival in small cell lung cancer
Limited treatment options are available for patients with this most aggressive type of lung cancer.
Read More
AZ’ Imfinzi to be funded for NHS use via CDF
AstraZeneca’s PD-L1 inhibitor Imfinzi will be made available on the NHS in England immediately for patients with locally advanced unresectable non-small-cell lung cancer.
Read More
AZ’ Imfinzi fails in head and neck cancer trial
AstraZeneca and MedImmune’s Imfinzi has failed to hit targets in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Read More
Setback for AZ’ Imfinzi lung cancer combination
AstraZeneca’s Imfinzi has failed to show a significant benefit over standard of care (SoC) chemotherapy on overall survival in certain patients with lung cancer.
Read More
AZ’ Imfinzi reduces risk of death by 32% in stage III NSCLC
AstraZeneca says Imfinzi is the first immunotherapy to show significant overall survival in a curative lung cancer treatment setting.
Read More
EC clears AZ’ Imfinzi for locally-advanced, unresectable NSCLC
AstraZeneca’s Imfinzi has been approved in Europe for the treatment of locally-advanced, unresectable non-small cell lung cancer (NSCLC).
Read More
AZ lung cancer combo fails to hit targets
A combination of immunotherapy drugs being tested by AstraZeneca in the third-line setting in patients with lung cancer has failed to slow disease progression or extend survival.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
